In this week’s Nature, researchers from the University of Massachusetts Medical School reported on the silencing of a third copy of chromosome 21 that causes Down’s syndrome in a cell culture model of the disorder, marking a step forward towards “chromosome therapy.” The scientists used zinc finger nucleases to insert an inducible transgene version of a gene called XIST into cultured stem cells from Down’s syndrome patients.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The US National Institutes of Health and the Food and Drug Administration have proposed changing gene therapy oversight, the Associated Press reports.

Nature News reports that the Salk Institute has asked for the scope of a gender discrimination lawsuit brought against it to be narrowed.

CNBC reports that the sequencing startup Veritas aims to sequence individuals who fall at extremes.

In PLOS this week: genotyping of indigenous North African goats, program to simulate evolve and resequencing studies, and more.